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EORTC Headquarters plays a unique role in coordinating and supporting large-
scale pan-European cancer clinical and translational research. Initially established
to provide efﬁcient methodological and coordinating services to the EORTC Research
groups and to ensure professional involvement of the organization, it has grown
over the years in step with an increasing number and complexity of cancer clinical
trials. Recent advances in laboratories around the world have shed light on the
biology of cancer, and EORTC Headquarters, armed with a competent and dedicated
staff, continues to advance the state of cancer clinical research and implement the
appropriate infrastructures to support the conduct of the next generation of cancer
clinical trials.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Background
For 50 years, the European Organisation for Research
and Treatment of Cancer (EORTC) has been the hub of
cancer clinical research in Europe. Under its umbrella,
dedicated networks of researchers and clinicians have
grouped together to conduct clinical and translational
cancer research that has had a profound effect on
cancer treatment not only in Europe, but worldwide.
A large number of currently available standard cancer
treatments are a direct consequence of this continued
and collaborative effort, and many of these achievements
are reported in the subsequent pages of this issue
of the European Journal of Cancer commemorating the
50th Anniversary of the EORTC.
As an academic research organization, the EORTC is
fulﬁlling its mission to develop, conduct, coordinate, and
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stimulate translational and clinical research in Europe to
improve themanagement of cancer and related problems
by increasing survival and also improving patient quality
of life (QOL).
To continue delivering on this mission in the future, the
EORTC evolves. Translational research, in ever increasing
complexity, is now integrated into EORTC clinical trials
in recognition that through translational research it will
be possible to develop drugs targeted at the biology of
the cancer and advance therapies based on individual
molecular and genetic tumor characteristics.
In all of its research efforts, the EORTC maintains
principles of independence to ensure the quality of
its studies. The protocol is designed by academia and
reviewed by an independent peer review committee,
the integrity of the database is controlled by an
independent group with a focus on the validity of the
primary endpoint, the statistical analysis and publication
are independently processed, and charters are drawn
for the use of biological materials. The principles of
independence assure the scientiﬁc community and the
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Fig. 1 – Structure of EORTC.
general public that practice-changing trials do indeed
meet the scrutiny of the scientiﬁc community and allow
rapid implementation of results. 1
The EORTC continuously strives to develop and reﬁne
the whole organization, both the network and the
infrastructure at EORTC Headquarters, to enable the
achievement of these clinical and translational cancer
research goals.
2. Structure of the EORTC
The EORTC is comprised of the General Assembly,
the Board, several committees, a network of scientists
and clinical investigators, and the Headquarters staff 2
(Fig. 1).
The EORTC Network comprises over 300 hospitals
and cancer centers in over 30 countries which include
some 2,500 collaborators from all disciplines involved
in cancer treatment and research. These collaborators
are organized into groups of scientists and clinicians,
each with a speciﬁc area of interest in cancer research.
These groups conduct clinical trials and participate in
translational research on all types of cancers using
a multidisciplinary approach and actively pursuing
international cooperation.
Within this network, EORTC committees oversee the
independence of the EORTC as well as the relevance and
scientiﬁc value of all of its research efforts (Table 1).
EORTC research offers an integrated approach to the
evaluation of innovative agents, a comprehensive clin-
ical trial program, multimodality therapeutic strategic
evaluation, and research projects incorporating QOL and
patient-reported outcomes when applicable. 3,4
The EORTC Clinical Research Division is mainly
involved in the conduct of clinical trials through disease-
oriented groups (Brain Tumor, Breast Cancer, Melanoma,
Leukemia, etc.), and modality-oriented cooperative
groups such as the Radiation Oncology and Quality of
Life Groups (Table 2).
In cooperation with the disease-oriented groups, the
EORTC Translational Research Division, which includes
the Pharmacology and Molecular Mechanisms, Pathobi-
ology, and Imaging Groups, focuses on the pre-clinical
testing of new anticancer agents, receptors, and tumor
Table 1 – EORTC Committees
NDAC: New Drug Advisory Committee
TRAC: Translational Research Advisory Committee
PRC: Protocol Review Committee
SAC: Scientiﬁc Audit Committee
QAC: Quality Assurance Committee
IDMC: Independent Data Monitoring Committee
MC: Membership Committee
IRB: EORTC Headquarters Institutional Review Board
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Table 2 – EORTC Research Groups
Clinical Research Division Translational Research Division
Brain Tumor Head and Neck Cancer Imaging
Breast Cancer Infectious Diseases Pathobiology
Cancer in the Elderly Leukemia Pharmacology & Molecular Mechanisms
Children’s Leukemia Lung Cancer
Cutaneous Lymphoma Lymphoma
Endocrine Tumors Melanoma
Gastrointestinal Tract Cancer Quality of Life
Genito-Urinary Cancers Radiation Oncology
Gynecological Cancer Soft Tissue and Bone Sarcoma
markers. It also provides support for translational
research projects conducted within the EORTC on
pharmacology and molecular mechanisms, pathology,
and imaging.
3. EORTC Headquarters: An historical perspective
EORTC Headquarters has evolved over the years and now
plays a central role in all EORTC endeavors, enabling
the conduct of complex clinico-genomic trials in a
challenging international regulatory environment. It is
a pan-European clinical research infrastructure based
in Brussels, Belgium, from where its various activities
are coordinated and run. Today, the 180 members of
the EORTC Headquarters staff handle some 6,500 new
patients enrolled each year in cancer clinical trials,
approximately 30 protocols that are open to patient entry,
over 50,000 patients who are in follow-up, and a database
of more than 180,000 patients.
This success was built over the years, for even though
the EORTC has been in existence since 1962, initially
there was no central organization to which EORTC Group
members could turn for statistical advice, support, and
data management. This was remedied in 1972 with the
establishment of the EORTC Data Center which was
able to provide the Groups with efﬁcient methodological
and coordinating services by a competent and dedicated
staff. 5
At about the same time, the US National Cancer
Institute grant funding the EORTC Coordinating Ofﬁce,
which had been in existence since 1969, was successfully
extended and helped support the EORTC Data Center
to “receive, review, process and analyze data for all
clinical studies conducted by all EORTC cooperative
groups”. Actual funding for the Data Center began
in November 1973, and operations began in earnest
in January 1974 with the appointment of a director,
Dr. Maurice Stacquet, a data clerk, Pat Mineur, and
overall support from Dominique Eeckhoudt, along with
some temporary statistical help. In August 1975 Richard
Sylvester joined the EORTC Data Center staff as the ﬁrst
full-time statistician, and over the years Richard was
instrumental in developing the Statistics Department
into a world class unit. 6,7
Over the years, the EORTC Data Center continued to
grow, keeping pace with an increasing number of clinical
trials which had passed 200 in 1990. Recruitment of
patients into EORTC trials had already surpassed 6,000
new patients per year, and support was needed mostly
in terms of data management and statistical support.
EORTC Data Center staff had increased to 29 members
in 1991.
4. 1991–2011: 20 further years of progress in
clinical trial methodology
In May 1990, the EORTC Data Center relocated from
the Institut Jules Bordet to its current address, and
in 1991 Prof. Franc¸oise Meunier was appointed as
Scientiﬁc Director. She rapidly became Director of the
Data Center Central Ofﬁce and in 1995 was appointed
as the ﬁrst EORTC Director General as a result of
expanding activities and the increase in staff needed to
face the challenges of modern clinical research. Quality
control procedures were expanded within the EORTC
Data Center, ﬁrst addressing key tools, such as the case
report forms (CRFs). At this time the ﬁrst EORTC Data
Center Procedures Manual was published. A Phase II Unit
was put in place to increase the efﬁciency and quality
control of phase II trials, and the ﬁrst series of on-
site monitoring visits were initiated. 8−10 Medical support
for EORTC Data Center activities continued to improve
with the start of the EORTC Fellowship Program in 1991,
followed later on by the addition of clinical research
physicians to ensure the required medical knowledge at
the EORTC Data Center and to provide support to the
clinical research.
The 1990s saw the gradual implementation of national
and supranational guidelines and regulations governing
the conduct of clinical research. Establishment of a
Regulatory Desk, a Pharmacovigilance Unit, and an
insurance program at the EORTC Data Center was a
natural response to this changing environment. 11 Such
professionalism was essential in the late 1990s and
early 2000s, and later this approach proved instrumental
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Fig. 2 – Areas where EORTC Headquarters has upgraded, both internally and externally, its cancer clinical and translational
research activities.
in enabling the EORTC to adapt to the regulatory
environment following the issuance of the 2001 EU
Clinical Trial Directive (2001 CTD). Armed with expertise
gained in these ﬁelds, the EORTC was suitably equipped
to voice the position and point of view of academic
clinical research in Europe. 12 In retrospect, it can be said
that through these prior efforts and accomplishments
the EORTC became a reference in Europe for its expertise
in all legal aspects related to the conduct of international
clinical research. Today, EORTC Headquarters is an active
member of many European initiatives dealing with the
challenges of conducting international clinical trials and
particularly for the revision of the 2001 CTD.
The last decade saw the original EORTC Data Center
evolve to a central coordinating facility that is now
responsible not only for coordinating the scientiﬁc
and methodological aspects of EORTC clinical trials,
but also for coordinating all aspects of operational,
regulatory, and legal matters. As a result, in 2009 it
was renamed EORTC Headquarters. In 2012, with a
staff of over 180 employees, EORTC Headquarters is
not just an operational infrastructure for the EORTC
network, but plays an integral role in the delineation and
implementation of EORTC scientiﬁc strategy established
by the EORTC Board.
Since 1985, the EORTC has participated in EU-funded
projects, and over the last six years the EU Programs
Ofﬁce has supported applications of some 45 proposals
and successfully achieved approximately 33% of these.
On the 50th anniversary of the EORTC, EORTC
Headquarters has become a central and indispensible
component in the implementation of comprehensive and
multifaceted EORTC research projects (Fig. 2). It is a major
European infrastructure sustaining the methodology of
cancer clinical research in the era of molecular biology
and tailored clinical study designs while pursuing its
original mission to support multidisciplinary trials aim-
ing at the establishment of state-of-the-art treatments
on an independent basis.
5. New partnerships with scientiﬁc and learned
societies
The paradigm shift in cancer clinical research instigated
by advances in molecular biology has led to a further
broadening of the EORTC’s multidisciplinary approach.
Information obtained from medical images and biolog-
ical materials are intricately involved in the decision
making processes for both patient treatment planning
and drug development for speciﬁc molecular entities.
These burgeoning technologies require advanced exper-
tise which is found within the membership of the EORTC
Translational Research Division Groups, and one that is
augmented by partnerships with appropriate scientiﬁc
networks. Partnership with learned societies increases
awareness among their respective memberships and
leads to wider recognition across disciplines.
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EORTC Headquarters has established partnerships
with the European Association of Nuclear Medicine, the
European Institute for Biomedical Imaging Research, The
European Society of Radiology, and the European Society
of Pathology in order to bring together cancer clinical
research methodology and the numerous speciﬁcities
of imaging and pathology. The acquired cross-expertise
has led to the establishment of guidelines for quality
assurance in these domains, and upgraded procedures
for optimal biobanking and biomarker qualiﬁcation are
good examples of this. In addition, cancer clinical trials
methodology for embedding imaging and translational
research are being addressed. With an eye towards en-
suring strong collaborations in the future, joint symposia
are being organized in order to bring disciplines together
for discussion of important clinical questions.
Precently, a partnership is being established with the
UK-based Sanger Institute. This will bring additional
strength through the forging of EORTC international
expertise with high sequencing capacities within the
structuring mold of multidisciplinary clinical trials.
6. Regulatory compliance
Following the implementation of the 2001 CTD in May
2004, EORTC Headquarters, acting as clinical trial sponsor
in addition to having extensive partnerships with the
pharmaceutical industry, systematically upgraded its
quality systems to comply with the new regulatory
requirements. These upgrades were particularly evident
within the Regulatory Affairs and Pharmacovigilance
Units that negotiate the complex regulatory constructs
involved in intergroup and industry cooperation. Experi-
ence gleaned in these areas resulted in EORTC represen-
tatives being placed in important roles in developmental
committees of various EU initiatives concerning the
practical implementation of legal requirements. 13
Establishment of nationally based liaison ofﬁces was
another action implemented in response to the 2001 CTD.
Nationally based liaison ofﬁces facilitate the implemen-
tation and conduct of EORTC trials by supporting both
the EORTC Regulatory Affairs Unit and the Investigators.
Such ofﬁces are currently active in France, the United
Kingdom, and Poland, and establishment of additional
ofﬁces in Germany and in the United States are under
discussion. Liaison Ofﬁces have proven their worth in
facilitating processes particularly for study activation.
7. Support for methodology and training
Cancer clinical research is constantly evolving, and
EORTC Headquarters has transformed its advanced
teaching courses which focused on classical method-
ologies to ones geared towards the biologically driven
features of contemporary cancer clinical research.
Furthermore, as an extension of its partnership with
other societies, additional courses were established. For
example, Good Clinical Practice Courses were established
in cooperation with the European Forum on Good Clinical
Practice and are offered complementary to EORTC
members. In house, the QOL Department has initiated
a very promising series of conferences addressing
symptom research and patient-reported outcomes, and
in September 2011 hosted the 2nd Symposium on
Quality of Life Research in the European Parliament.
This symposium offered a unique opportunity for key
EU legislators, cancer researchers, and European patient
groups to interact with one another, foster greater
collaboration, and review QOL strategies.
Training the next generation of clinical oncologists
is of utmost importance in furthering the EORTC
mission, and since 1991 the EORTC Headquarters-
based Fellowship Program has enabled well over one
hundred young scientists and physicians (not only
oncologists but also surgeons and those with other
medical experience) to learn about the methodology of
clinical research, a discipline not necessarily taught in
medical schools. Fellows beneﬁt from the best training
in the cancer clinical trial setting; some have later joined
the healthcare industry, many others have pursued
academic careers and remain in contact with the EORTC
as investigators, while several fellows later joined the
EORTC Headquarters staff.
Since 1996, the EORTC has offered a course on clinical
trial statistics for non-statisticians, i.e., medical doctors,
data managers, etc. This course introduces the statistical
principles which form the basis for the design and
analysis of cancer clinical trials.
EORTC members and staff have been involved as
faculty for the Flims workshop since its inception. This
course entails intensive protocol development sessions
with cancer clinical trials experts giving participants an
in-depth overview of the design and conduct of high-
quality clinical trials.
8. Intergroup cooperation
Over the years the European cancer clinical trial land-
scape has changed dramatically, and several national,
disease-oriented clinical research groups have emerged.
As a result the EORTC has diversiﬁed its partnerships,
and its portfolio of intergroup trials has increased. 14,15
In line with the complexity of the regulatory framework,
the activities and responsibilities in these intergroup
trials must be clearly identiﬁed and well coordinated
upfront when trials are initiated, and in this context the
EORTC Headquarters International Regulatory Affairs/
Intergroup Ofﬁce is intricately involved.
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In this complex clinical trial environment, it is critical
that the academic sector avoids a duplication of effort. 16
In this respect the EORTC, as an international and
multidisciplinary organization, has a clearly deﬁned
plan of action which has enabled it to pursue an
agenda complementary to that of the global cancer
clinical research community. This has placed the EORTC
in a unique position to facilitate implementation of
innovative concepts of treatment in clinical practice as
well as address rare tumors and fragmented populations
of frequent tumors.
EORTC Headquarters now establishes large interconti-
nental trials with US-based cooperative groups and also
with NCI-Canada andAustralia. EORTC Headquarters has
been able to provide its groups with the infrastructure
that allows them to pursue their scientiﬁc agenda
outside the classical path of EORTC-only trials. Since
1973, EORTC Headquarters has received uninterrupted
support from the US National Cancer Institute, and this
constructive relationship continues to evolve.
9. Functioning of EORTC Headquarters
All of the above improvements and required evolution
have profoundly impacted the EORTC structure. EORTC
Headquarters has been revisiting its set of Standards
Operating Procedures. It now has dedicated departments
and units that support translational and imaging
research as well as quality assurance programs. Never-
theless, EORTC Headquarters remains a reasonably sized
structure where pragmatism in the interest of medical
progress and the patient community is a daily concern
despite a more complex international environment. 17
The day to day functioning occurs horizontally through
multidisciplinary scientiﬁc teams, while the reporting
chart ensures cohesion among the various departments
and units.
10. Technical expertise platforms and quality
assurance programs
Probably one of the most remarkable recent achieve-
ments is the implementation of transversal group activ-
ities aimed at promoting the EORTC scientiﬁc strategy.
Guidelines to evaluate the Response toTreatment in Solid
Tumors (RECIST 18) were developed by the EORTC together
with the National Cancer Institute of the United States
and the National Cancer Institute of Canada Clinical
Trials Group. Today, the EORTC Imaging group is taking
a new leading role in supporting the development of
imaging projects such as in the revision of RECIST, 19
in establishing new imaging criteria for decision rules,
and developing projects aimed at validating new imaging
biomarkers. These activities will lead to improvements
in the quality and consistency of the evaluation of
new cancer treatments within EORTC clinical trials
using imaging technologies such as CT, PET[-CT], MRI
and others that are used for treatment deﬁnition
for radiotherapy, staging, prediction and evaluation of
response, or pathology. 20
Following high quality control standards, not only
from the scientiﬁc perspective but also from regulatory
compliance requirements, secures a reliable technical
infrastructure for the development of new molecular
entities in cooperation with the pharmaceutical industry.
Central storage and online review of medical images has
become a reality for international clinical trials.
Over the years, the EORTC and particularly the EORTC
Radiation Oncology Group have been actively engaged
in Quality Assurance in Radiotherapy. More recently, the
EORTC implemented comprehensive quality assurance
program services for radiotherapy which ensures that
radiotherapy is delivered at the highest standards across
all EORTC clinical trials.
Similarly, prospective biobanking and principles on
human biological material collection, storage, and use
provide the EORTC, under the guidance of its Transla-
tional Research Division, with a consistent yet ﬂexible
approach in line with national legal requirements. 21,22
11. EU programs
Since 1985, the EORTC has participated in more than 30
research projects funded by the European Commission
in various cancer-related ﬁelds including quality of life
assessment, leukemia research, supportive care, telem-
atics, biological response modiﬁers, pharmacokinetics,
treatment costs evaluation, meta-analyses of cancer
clinical studies, biomarkers, genomics, tissue banking,
fellowships, and research infrastructures. Support, op-
timization, and coordination of EORTC participation in
EU-funded projects is managed through the EU Program
Ofﬁce.
The EORTC participates in various FP6 projects such as
TRANSBIG [Translating molecular knowledge into early
breast cancer management building on the BIG (Breast
International Group) network for improved treatment
tailoring]. The objective of TRANSBIG is the validation
of a genomic signature to proﬁle early breast cancer
patients and then adapt the treatment accordingly. The
EORTC 10041 MINDACT trial, managed by the EORTC, is
being conducted to validate this genomic signature and
involves the EORTC Breast Cancer Group. The EORTC also
participates in the CHEMORES project (Molecular mecha-
nisms underlying chemotherapy resistance, therapeutic
escape, efﬁcacy and toxicity).
Participation in FP7 projects includes ECRIN-PPI (Eu-
ropean Clinical Research Infrastructures network and
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biotherapy facilities: preparation phase for the infras-
tructure); ICREL (Impact in clinical research of European
legislation); EuroCancerComs (Establishing an efﬁcient
network for cancer communication in Europe) and the
Innovative Medicine Initiative (IMI) project PharmaTrain
(Pharmaceutical MedicineTraining Programs).The EORTC
is participating in the BBMRI project (Biobanking
and Biomolecular Resources Research Infrastructure:
preparation phase for the infrastructure) as an associated
organization.
The EORTC is participating in several recently approved
FP7 projects which began in 2010: the Network of
Excellence EurocanPlatform (A European Platform for
Translational Cancer Research); Euro-BioImaging (Euro-
pean Biomedical Imaging Infrastructure), the preparatory
phase of an ESFRI Research infrastructure. The EORTC
is coordinating the recently approved IMI project QUIC-
CONCEPT (Quantitative Imaging in Cancer: Connecting
Cellular Processes with Therapy).
12. Support to the EORTC scientiﬁc strategy
To ensure that the EORTC Research Groups beneﬁt
from the newly implemented technical expertise plat-
forms and adhere to the EORTC scientiﬁc agenda,
the Early Project Optimization Department (EPOD)
provides support to groups to tailor speciﬁc trials or
overall tumor-oriented development plans compatible
with these principles. EPOD facilitates interaction with
the pharmaceutical industry where required, optimizes
interaction with other EORTC groups, and acts to avoid
duplication of clinical research effort both within and
outside of the EORTC.
The Statistics Department has been instrumental in
supporting new trial designs and statistical approaches
to decision rules for proof of concept/early clinical
trials. Integration of biomarkers have been supported
by the now fully functioning Translational Research and
Imaging Department which has structured approaches
to correlative and integrated biomarkers and the
implementation of the new biobanking policy (all EORTC
policies are available at www.eortc.be).
Following the initiative taken by the EORTC Board,
EORTC Headquarters has actively contributed to the
creation and coordination of NOCI, a Network Of Core
Institutions that offers an integrated infrastructure
capable of assuring high-quality clinical trials, patient
accrual potential, and intrinsically designed translational
research. NOCI is a concept to facilitate the EORTC
scientiﬁc agenda as well as a ﬂag attached to certain
trials bearing speciﬁc features, so-called clinico-genomic
trials. Early “proof of concept” trials providing go/no go
decisions, understanding the mechanism of action of
treatments, looking for host/tumor-related molecular
discriminates predictive of toxicity or activity have
revolutionized the way early clinical trials should be
conceived, designed, and conducted.
13. Information technology development
Additional challenges related to the paradigm shift
leading towards clinico-genomic trials have impacted
the systems supporting the performance of clinical
trials. These systems now ﬁnd themselves in a constant
state of evolution. The EORTC’s web-based remote data
capture (VISTA RDC) and registration/randomization
(ORTA) systems have recently been upgraded with an
integrated bio-sample management tool that allows
online follow up of biological material samples, and in
the near future these will be linked with the virtual
tumor bank. 22 Due to the prevalence of double blind
placebo controlled studies, ORTA has been upgraded
to allow optimal management of such studies. In
2010, new programs to improve data timeliness and
form request efﬁciency were installed, and a fully
integrated pharmacovigilance system has improved
serious adverse events reconciliation and optimized
safety reporting according to European Medicines Agency
and US Food and Drug Administration regulations.
To facilitate data exchange with partners or industry
and to beneﬁt from the CDISC structured format, our
clinical trial database and VISTA RDC are being upgraded
to CDISC standards. All EORTC information technology
systems are FDA 21 CFR Part 11 compliant.
14. Quality of Life Department
QOL is a ﬁeld in which the EORTC has played a leading for
more than three decades. The EORTC recognized in the
early 1980s that there was a need for robust measures
that could evaluate, in a systematic and rigorous manner,
the patient’s perspectives. The EORTC Quality of Life
Group (QLG) was thus created, and it has worked hard
to ensure that QOL tools are accessible globally for all
researchers for most disease sites. To date, the EORTC
has more than 30 QOLmodules that have been translated
into 66 languages.
In 1993, EORTC Headquarters recognized that while
the QLG could provide robust and validated tools,
EORTC Headquarters needed a specialized department.
Now, nearly 20 years since its creation, the EORTC
QOL Department has overseen the implementation of
QOL assessment tools into over 130, mainly phase III,
EORTC clinical trials, and has a vigorous research
program with more than 40 ongoing methodological and
clinical research studies. The results of combining robust
tools within the framework of rigorous EORTC clinical
trials, with motivated investigators from all groups,
means QOL measures now impact treatment decisions.
The EORTC is currently working with the European
Medicines Agency to develop new QOL guidance for the
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better regulation of new oncology compounds. We hope
our initiatives ensure that the patients’ voices are heard
and will serve as an important factor in understanding
the consequences of cancer and its treatment.
15. Actions in the legal framework
EORTC Headquarters has been active at the European
level to voice the speciﬁc needs of academic research
with regard to the revision of 2001 CTD. 23,24 EORTC
Headquarters has played a major role in the currently
proposed revision of this directive that is now being
considered by the European Commission and will be
submitted to the European Parliament most likely in
2012.
More concretely, EORTC Headquarters through its
Regulatory Affairs Unit was the ﬁrst European academic
organization to pilot the Voluntary Harmonization
Procedures implemented by the national competent
authorities that enable shorter approval timelines for
trial activation.
16. Streamline–Simplify–Harmonize
Increased regulatory complexity in conjunction with
sophisticated trial designs that require access to medical
images and biological material is a threat to timely and
efﬁcient incorporation of innovative ideas into active
clinical trials. EORTC Headquarters has set up a concept
referred to as Streamline–Simplify–Harmonize whose
premise is to actualize constant control of timelines for
activating trials and identify emerging bottlenecks at an
early stage so as to facilitate rapid intervention through
the project management platform. EORTC metrics are
closely followed and are now prospectively presented
to the network of investigators and partners, and early
benchmarking of these has not highlighted any major
deviances when compared to that of industry or other
academic research groups.
17. Future perspectives: molecular biology-based
treatments
The work that the EORTC has achieved thus far is not an
end, rather these achievements are part of a continuous
transformation process in the pursuit of knowledge. New
means for advancing the standards of care will need to
be created, and new directions will be inﬂuenced by as
yet unrecognized parameters. Innovative approaches will
ultimately lead to medical progress and success.
EORTC Headquarters has already taken steps to ad-
dress the present and short-term challenges associated
with integrating information from translational research,
imaging, and biological materials into cancer clinical
trials. Models for combining several data sets into a
multidisciplinary approach for cancer treatment progress
will require interactive and high-quality assurance
programs; one reason why EORTC Headquarters has built
QA measures into its new technical expertise platforms.
Incorporation of these data will require robust and struc-
tured processes, and while the challenges associated
with their integration should not be underestimated,
pragmatism and vigilance on metrics of deliverables
will be critical. This is the rationale behind the close
monitoring of EORTC Headquarters activities through the
concept of Streamline–Simplify–Harmonize which aims
to track the required and permanent adjustment of any
activity.
18. The evolving partnerships with the
pharmaceutical industry
The EORTC has successfully conducted a series of trials
in partnership with industry and which jointly changed
practice and serve either prospectively or retrospectively
drug registration in the best interest of all parties and
therapeutic improvement for patients. 25−28
Moving forward, new forms of partnerships between
industry and academia will need to be envisioned as
modern clinical trials demand long-term maintenance
of technical and cross-validated infrastructure which is
neither in the remit nor in the capacity of industry.
New agents can be best and rapidly developed if studied
in high quality academic environments. Molecular
sub-division of tumor entities requires efﬁcient and
transnational networks for large screening programs for
complex trials which cannot be administered outside
optimally controlled and well oiled infrastructures.
Complementary commercial and academic agendas
need to evolve to ensure the principles of independence
that are so critical for the scientiﬁc and patient
community. Both parties need to address data access
policies for shared knowledge and stimulate scientiﬁc
thinking while new approaches to intellectual property
challenges need to be developed. While integration
of agendas alongside efﬁcient developmental activities
avoiding duplication of effort should be a cost efﬁcient
approach, funding will remain a major challenge for
complex cutting-edge research. 29
Dating back to the Phase II Unit mentioned previously,
the EORTC has made substantial progress in facilitating
interactions with industry for drug development. Today,
the operations to conduct clinical trials and data
exchange policies are wide open with respect to
partnership models. That said, it is critical for both
industry and academia, when partnering on trials which
go beyond the single drug development approach, that
the principles of academic independence are respected.
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The forms and the methods of cooperation with industry
are constantly evolving but are based on a good balance
between a few criteria ensuring academia independence
and sets of procedures for full visibility by industry.
19. Cooperation with patient organizations and
cancer leagues
The EORTC has established relationships with numerous
patient organizations and cancer leagues throughout
Europe. In these relationships, the EORTC beneﬁts from
the expertise of patients for making information sheets
and informed-consent forms more patient friendly
and for the dissemination of information concerning
progress in EORTC cancer clinical trials. In addition,
EORTC members and staff have offered their expertise
and served as speakers in courses offered by patient
organizations and the cancer leagues, and several
EORTC courses have been made available free of
charge to patients. The EORTC is also participating in
EUPATI (European Patients’ Academy on Therapeutic
Innovation), an Innovative Medicine Initiative to create
better educational and information tools for patients
concerning pharmaceutical innovations and also to raise
patient awareness of and participation in pharmaceutical
research and development.
20. Looking forward
For 50 years, the EORTC has conducted and coordinated
pan-European cancer clinical research and large-scale
clinical trials in Europe, and, as documented in this EJC
supplement, many currently available standard cancer
treatments are a direct result of this continued and
systematic effort. The EORTC, however, is not content to
rest on its laurels and will continue to adapt its structure
and function in order to meet future challenges.
Investigator-driven Clinical Trials should be a top
European priority, and new forms of funding for practice-
changing trials should be created. Patient organizations
need to be involved in this evolution, and cancer leagues
should work with their respective national governments
in order to see the value in supporting large international
programs, as a complement to their support for national
programs, when these international programs are proven
to be of value to their contributors. Again, we should
avoid duplication of effort.
National health funds and hospital administrations
should see clinical research as a long-term investment
for the beneﬁt of patients but also for the continuing
education of medical professionals, and contribute ac-
cordingly. Cost containment while preserving European
capacity of excellence andmedical progress will certainly
be the greatest challenge all stakeholders need to take
collegially forward. The EORTC is ready to meet this
challenge.
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